Alnylam Pharmaceuticals. has been granted a patent for a method using double-stranded RNA (dsRNA) to inhibit the expression of the G-alpha q subunit (GNAQ) in cancer cells. The method involves introducing specific dsRNA sequences into the cells to degrade GNAQ mRNA transcripts. GlobalData’s report on Alnylam Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Alnylam Pharmaceuticals, siRNA gene silencing was a key innovation area identified from patents. Alnylam Pharmaceuticals's grant share as of June 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Inhibiting gnaq expression in cancer cells using dsrna
The granted patent US12031133B2 outlines a method for inhibiting the expression of the G-alpha q subunit (GNAQ) in cancer cells through the introduction of isolated double-stranded ribonucleic acid (dsRNA). The method involves delivering a dsRNA that includes a sense strand (SEQ ID NO:1409) and an antisense strand (SEQ ID NO:1410), each ranging from 19 to 30 nucleotides in length. Following the introduction of this dsRNA into the cancer cell, the cells are maintained for a duration sufficient to achieve degradation of the GNAQ mRNA transcript, thereby effectively reducing GNAQ gene expression. The patent specifies that this inhibition can be quantified, with potential reductions of at least 20%, 40%, 60%, or even 80% in expression levels.
Additionally, the patent details specific cancer cell lines suitable for this method, including A549 (lung carcinoma), A375 (malignant melanoma), and various uveal melanoma cell lines such as GNAQmut, OMM1.3, and MEL202. The dsRNA can also incorporate modified nucleotides, including 2'-O-methyl and 2'-fluoro modifications, enhancing its stability and efficacy. Furthermore, the patent describes a therapeutic application of this method, proposing the administration of the dsRNA to humans diagnosed with cancers associated with GNAQ expression, such as uveal melanoma and cutaneous melanoma, among others. This innovative approach aims to provide a targeted treatment strategy for cancers driven by GNAQ, potentially improving patient outcomes.
To know more about GlobalData’s detailed insights on Alnylam Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
